Skip to content

Developing a broad and differentiated portfolio of drug candidates to address unmet needs within and beyond psychiatry


Our psychiatric pipeline features a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment alternative for depression, and ultimately, to address a broad range of unmet needs

ProgramIndicationPhase IPhase IIPhase IIPhase IMilestone
Phase I Initiation
1H 2022

Beyond Psychiatry

Eleusis is exploring the exciting potential of psychedelics beyond psychiatry - as immunomodulatory and neuroprotective medicines. These and other areas are detailed in Science. Welcome to the clinical evolution of psychedelics.

Eleusis is a life science company based in London and New York, dedicated to transforming psychedelics into medicines

General & Media Inqueries

Careers Opportunities


New York